Date: 2011-10-25
Type of information: Licensing agreement
Compound: GlymaxX® Antibody Glyco-Engineering technology
Company: Probiogen (Germany) Inhibrx (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: ProBioGen and Inhibrx have signed a multi-program license deal on ADCC-enhanced therapeutic antibodies. ProBioGen’s GlymaxX ® ADCC enhancement technology and mammalian cell line development and manufacturing services will be used to advance therapeutic antibodies generated by Inhibrx’s discovery platforms. The agreement initially covers development services for several undisclosed first-in-class and best-in-class antibodies with enhanced ADCC (Antibody-dependent cellular cytotoxicity assays ) potency, as well as cell line and process development for other recombinant therapeutic proteins.
Financial terms: ProBioGen will receive both milestone-dependent license fees, as well as fee-for-service-based payments for its technologies and efforts. Further financial details were not disclosed.
Latest news:
